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ABSTRACT
Background. FOLFIRINOX prolongs survival in patients
with metastatic pancreatic cancer and may also benefit
patients with locally advanced pancreatic cancer (LAPC).
Furthermore, it may downstage a proportion of LAPC into
(borderline) resectable disease, however data are lacking.
This review assessed outcomes after FOLFIRINOX-based
therapy in LAPC.
Methods. The PubMed, EMBASE and Cochrane library
databases were systematically searched for studies pub-
lished to 31 August 2015. Primary outcome was the (R0)
resection rate.
Results. Fourteen studies involving 365 patients with
LAPC were included; three studies administered a modified
FOLFIRINOX regimen. Of all patients, 57 % (n = 208)
received radiotherapy. The pooled resection rate was 28 %
(n = 103, 77 % R0), with a perioperative mortality of 3 %
(n = 2), and median overall survival ranged from 8.9 to
25.0 months. Survival data after resection were scarce, with
only one study reporting a median overall survival of
24.9 months in 28 patients. A complete pathologic response
was found in 6 of 85 (7 %) resected specimens. Dose
reductions were described in up to 65 % of patients, grade 3–
4 toxicity occurred in 23 % (n = 51) of patients, and 2 %
(n = 5) had to discontinue treatment. Data of patients treated
solely with FOLFIRINOX, without additional radiotherapy,
were available from 292 patients: resection rate was 12 %
(n = 29, 70 % R0), with 15.7 months median overall sur-
vival and 19 % (n = 34) grade 3–4 toxicity.
Conclusions. Outcomes after FOLFIRINOX-based ther-
apy in patients with LAPC seem very promising but further
prospective studies are needed, especially with regard to
survival after resection.
Pancreatic ductal adenocarcinoma has very poor sur-
vival rates. Surgical resection with adjuvant chemotherapy
offers the best survival but is only feasible in approxi-
mately 20 % of patients.1 Forty percent of patients present
without distant metastases but with extensive vascular
involvement prohibiting upfront resection, known as
locally advanced pancreatic cancer (LAPC).1 In these
patients, gemcitabine monotherapy (sometimes combined
with radiotherapy) has been the standard palliative treat-
ment for decades. Unfortunately, response rates are low
without clear improvement in survival.2
Recently, the superiority of FOLFIRINOX, a combina-
tion of 5-fluorouracil, oxaliplatin, irinotecan and
leucovorin, over gemcitabine monotherapy in patients with
metastatic pancreatic cancer was demonstrated: a response
rate of 31.6 versus 9.4 % and a median overall survival of
11.1 months versus 6.8 months (p\ 0.001) has been
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observed.3 The comparable poor prognosis of LAPC and
the lack of beneficial therapies have also led to the
administration of FOLFIRINOX, sometimes combined
with radiotherapy, in patients with LAPC; however, no
randomized trials have been conducted on this topic.
Several observational studies on FOLFIRINOX-based
treatment included both patients with LAPC and borderline
resectable pancreatic cancer. Borderline resectable disease
is defined by the National Comprehensive Cancer Network
(NCCN) as an arterial involvement of less than 180 degrees
or a venous involvement with options for reconstruction.4
The inclusion of patients with borderline resectable pan-
creatic cancer may positively influence outcomes as these
patients have a higher chance of resection in advance.
Therefore, the aim of this study was to evaluate the results
of FOLFIRINOX-based treatment only in patients with
LAPC, considering (R0) resection rate as the primary
outcome.
METHODS
This systematic review was performed according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines.5
Search and Selection
The PubMed, EMBASE, and Cochrane Library data-
bases were systematically searched for studies published
from 2005 to 31 August 2015. Duplicates were removed
and studies published in languages other than English were
excluded. Three authors (MW, SR, JV) independently
screened articles by title and abstract and, if applicable, the
full articles for eligibility based on predefined inclusion
and exclusion criteria. Discordant judgments were
addressed by consulting a fourth author (LR). The refer-
ence lists of all included papers were searched manually to
identify missed, but potentially relevant, studies.
Eligibility Criteria
Retrospective and prospective studies on FOLFIRINOX
in patients with LAPC, reporting (R0) resection rate, sur-
vival, response rate or toxicity, were eligible for inclusion
in our study. Conference abstracts or case reports (i.e.
sample size of fewer than five patients) were excluded.
Assessment of Methodological Quality
The level of evidence was classified and a classical risk
of bias assessment was applied for all included studies
according to the Oxford Centre for Evidence-Based
Medicine (CEBM) Critical Appraisal Skills Programme
(CASP) 2004.6,7
Data Collection
Study design, study population, sample size,
resectability criteria and treatment regimen were extracted
from the included studies. Primary outcome was the (R0)
resection rate. Secondary outcomes were postoperative
complications, pathological response, overall survival,
response rate, CA19-9 response, and toxicity. In addition, if
FOLFIRINOX treatment was followed by radiotherapy,
outcomes during FOLFIRINOX administration before the
start of radiotherapy were additionally extracted to get
more insight into the outcome for solely FOLFIRINOX
treatment. Corresponding authors were approached when
data were missing or could not be extracted from the
article, or if no data were presented for the LAPC popu-
lation separately.
Statistical Analysis
Overall (R0) resection rate, postoperative complications,
complete pathologic response, response rate, CA19-9
response, and toxicity were calculated. A meta-analysis of
overall survival was not performed because of substantial
heterogeneity between studies and lack of individual
patient data.
RESULTS
Fourteen studies involving 365 patients (one prospective
observational study 10 and 13 retrospective studies 8,9,11–21)
were included (Fig. 1). No randomized trials were
available. LAPC was defined according to the
National Comprehensive Cancer Network (NCCN)
(n = 4),4,11,12,18,21 the consensus statement of the Ameri-
can Hepato-Pancreato-Biliary Association [AHPBA/SSAT/
SSO] (n = 3),8,9,14,22 or based on consensus within the
multidisciplinary team (n = 2).10,17 Five articles did not
define LAPC,13,15,16,19,20 and all studies had a substantial
risk of bias (Table 1).
Treatment Regimen
FOLFIRINOX was administered as single treatment in
four studies 10,12,13,15 and combined with radiotherapy in
10 studies.8,9,11,14,16–21 Three of the 14 studies adminis-
tered a modified FOLFIRINOX regimen from the
beginning of therapy by eliminating the bolus of fluo-
rouracil,16 in addition to lowering the dose of irinotecan,8
or by a starting dose of 80 % of the intensity of the
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FOLFIRINOX regimen.21 One study administered a mod-
ified regimen in 68 % of all first cycles.20 In the remaining
10 studies, FOLFIRINOX was administered as per the
PRODIGE 4/ACCORD 11 trial protocol at the start, but
also reported on a dose-reduction during the course of
treatment for 63 % of total cycles and in up to 65 % of
patients.3,9–15,17–19 The median number of cycles was
reported in five studies and ranged from four to
eight.8,11,17,20,21 Five studies reported FOLFIRINOX to be
first-line treatment.12,14,15,17,21 Patients who had progres-
sion under FOLFIRINOX treatment and subsequent
radiotherapy were treated with second-line chemotherapy
in two studies.17,21 After resection, adjuvant gemcitabine-
based chemotherapy was reported by two studies, as well
as additional combined chemoradiotherapy by one
study.8,14,15 The remaining seven studies did not reported
on prior, second-line, or adjuvant therapy.9,10,13,16,18–20
Overall, 208 of 362 patients (57 %) were treated with
additional radiotherapy after FOLFIRINOX treatment
(Table 2). Radiotherapy was delivered through conven-
tional treatment,8,11,14 intensity-modulated radiation
therapy (IMRT),16,17,19,21 or as stereotactic body radiation
therapy (SBRT).9,18 One study did not report on the details
of radiotherapy.20 Radiation was combined with
chemotherapy in six studies.8,11,14,16,19,21 The chemosen-
sitizer, as part of the chemoradiation, differed between
gemcitabine, capecitabine, 5-fluorouracil, or a combina-
tion. The total administered dose of radiotherapy ranged
from 36 to 54 Gy, given in fractions ranging from 3 to 30.
Three studies did not report on the dosage of
radiotherapy.16,20,21
Resection Rate and Postoperative Outcomes
Each of the 14 studies reported on resection rates, with a
total of 28 % (n = 103) after a median of five to eight
cycles of FOLFIRINOX and additional radiotherapy in
66 % of patients (56 of 85 patients with available data)
(Table 2).9,10,12–18,20,21 Of these, 10 studies reported a total
R0 resection rate of 77 % (n = 72).8,9,11,14–19,21 Morbidity
after resection was reported in three studies including 64
patients, and ranged from 20 % grade 3–4 to 60 % overall
complications.11,17,21 Morbidity was specified for 33
patients, with postoperative infection (n = 5) and bleeding
(n = 3) as the most common cause. Pancreatic fistula was
reported in one patient, and median hospital stay ranged
from 6 to 7 days.11,21 Perioperative mortality, reported by
five studies, was 3 % (n = 2).8,9,17,18,21 In total, 6 of 85
(7 %) resection specimens showed a complete pathologic
response (Table 2).8,11,12,15,17–19,21
One study compared patients who proceeded to surgery
with those who did not (n = 31 and n = 70, respectively).
FIG. 1 Study selection process
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Hepatic artery and unreconstructable venous involvement
were more common in the group that proceeded to resec-
tion compared with celiac trunk, superior mesenteric
artery, or multiple vessel involvement (p = 0.001).21
Another study did not reach significance when comparing
arterial involvement with venous involvement in resected
patients.17 No studies specified vascular involvement in
degrees.
Eight studies reported the resection rate for solely
FOLFIRINOX treatment, without additional radiotherapy,
with a pooled resection rate of 12 % (n = 29).9,10,12–15,17,21
In addition, four of these studies reported 14 R0 resections
(70 %) from a total of 20 resections 9,14,15,21 without any
complete pathologic response (Table 3).
Median Overall Survival
The median overall survival was reported in five studies
and ranged from 8.9 to 25 months; of these patients, 64 %
were treated with radiotherapy.9,10,17,19,21 In three studies,
median survival was not reached.11,12,20 One study showed
a 1-year survival of 83 %, in which the majority of patients
(91 %) were treated with radiotherapy.12 A second study
showed a 3-year survival of 7 %; none of the patients
received radiotherapy (Table 2).11
In addition, one study reported a median overall survival
of 24.9 months in 28 patients who underwent pancreatic
resection.17 Resection was preceded by radiotherapy in 24
patients. In two other studies, survival data after resection
were available from only two patients.9,19 Only one study
treated LAPC patients with solely FOLFIRINOX, without
additional radiotherapy or resection, and reported a median
overall survival of 15.7 months (Table 3).10
Response Rate and CA-19.9 Response
Seven studies reported on response rates.8,10–12,17,19,21
Almost all defined response rate as complete or partial
response according to Response Evaluation Criteria In Solid
Tumors (RECIST) criteria,11–13,16,17,19–21 and one according
to the World Health Organization (WHO) criteria.10 Of the
238 patients who were treated with FOLFIRINOX, 67 % of
patients received additional radiotherapy, which led to
response rates ranging from 9 % (n = 2) to 50 % (n = 8),
with a total response rate of 29 % (n = 76) (Table 2). CA-
19.9 reduction was reported in three studies: an overall












Response rate Median OS (months) Grade 3–4
toxicity
Blazer et al.8 25 15/25 (60) 11/25 (44) 10/11 (91) 0/11 (0) 2/23 (9)a NR NR
Boone et al.9 13b 5/10 (50) 2/10 (20) 1/2 (50) NR NR 8.9 5/10 (50)
Conroy et al.10 11c 0 (0) 0/11 (0) NA NA 3/11 (27) 15.7 NR
Faris et al.11 22 20/22 (91) 5/22 (23) 5/5 (100) 1/5 (20) 8/22 (36) NRE, 3-year 7 % NR
Gunturu et al.12 16 0 (0) 2/16 (13) NR 0/2 (0) 8/16 (50) NRE, 6-month 94 %;
12-month 83 %
NR
Hohla et al.13 6 0 (0) 2/6 (33) NR NR NR NR NR
Hosein et al.14 14 9/14 (64) 6/14 (43) 5/6 (83) NR NR NR NR
Kraemer et al.15 7 0 (0) 1/7 (14) 0/1 (0) 0/1 (0) NR NR NR
Mahaseth et al.16 20 10/20 (50) 4/20 (20) 3/4 (75) NR NR NR NR
Marthey et al.17 77 54/77 (70) 28/77 (36) 25/28 (89) 4/28 (14) 22/77 (28) 21.6 20/77 (26)
Mellon et al.18 21 21/21 (100) 5/21 (24) 5/5 (100) 0/5 (0) NR NR NR
Moorcraft et al.19 13 7/13 (54) 2/13 (15) 2/2 (100) 1/2 (50) 4/13 (31) 18.4 7/13 (54)
Peddi et al.20 19 4/19 (21) 4/19 (21) NR NR NR NRE 5/19 (26)
Sadot et al.21 101 63/101 (62) 31/101 (31) 16/29 (55)d 0/31 (0) 29/101 (29) 25 14/101 (14)
Overall 365 208/362 (57) 103/362 (28) 72/93 (77) 6/85 (7) 76/263 (29) 51/220 (23)
Data are expressed as n (%) unless otherwise specified
OS overall survival, NA not applicable, NR not reported, NRE not reached, LAPC locally advanced pancreatic cancer
a Two patients died before the restaging scan
b Three patients refused treatment or were lost to follow-up
c One patient had a local recurrence
d Two pathology reports were pending
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[30 % reduction in 70 % of patients, an overall [50 %
reduction in 54 % of patients, and a normalization of the
concentration in 35 % of all patients.8,11,17
In case of solely FOLFIRINOX treatment, response
rates ranged from 9 % (n = 2) to 50 % (n = 8), with a
total of 23 % (n = 39) (Table 3). Three studies that
administered subsequent radiotherapy in selected patients
reported response rates before and after radiotherapy, and
showed an additional response ranging from 0 % (n = 0)
to 9 % (n = 9) due to radiotherapy treatment.8,11,21
Toxicity
Five studies reported a 23 % (n = 51) grade 3–4 toxi-
city, without grade 5 toxicity (Table 2).9,17,19–21 None of
the studies reported specifically on the toxicity caused by
radiation. When considering toxicity for FOLFIRINOX
alone, two studies reported a total grade 3–4 toxicity rate of
19 % (n = 34) and no grade 5 toxicity (death)
(Table 3).17,21 The most common grade 3 and 4 compli-
cations were neutropenia (10 %) and nausea or vomiting
(9 %).9,17,19,20 Eight studies reported on discontinuation of
treatment due to unacceptable toxicity, with a pooled dis-
continuation rate of 2 % (n = 5).10,11,14,16–18,21
DISCUSSION
This systematic review on clinical outcomes after
FOLFIRINOX-based treatment for LAPC demonstrated a
28 % resection rate, of which 77 % were R0, and a median
overall survival ranging between 8.9 and 25.0 months.
Fifty-seven percent of these patients were treated with
additional radiotherapy. These data suggest that FOLFIR-
INOX-based treatment is indeed a promising option for
patients with LAPC, with acceptable toxicity (23 % grade
3–4 complications). After surgical resection, survival data
were lacking as only one study reported a median overall
survival of 24.9 months.17
One previous review included studies published up to
March 2014 and reported resection rates from six studies.23
The current review, including 14 studies, gives an updated
overview and shows other clinical outcomes after FOL-
FIRINOX treatment specifically in patients with LAPC. As
expected, the overall R0 resection rates reported in our
review (70–77 %) are slightly lower, as reported by two
recent studies (84–92 %) on borderline resectable dis-
ease.24,25 Surgical outcomes post-resection seem
comparable with outcomes in upfront resectable patients,
although still based on immature data.26–28













Median OS (months) Grade 3–4
toxicity
Blazer et al.8 25 – – – 2/23 (9)a NR NR
Boone et al.9 13b 2/10 (20) 1/2 (50) NR NR NR –
Conroy et al.10 11c 0/11 (0) NA NA 3/11 (27) 15.7 NR
Faris et al.11 22 – – – 6/22 (27) – NR
Gunturu et al.12 16 2/16 (13) NR 0/2 (0) 8/16 (50) NRE, 6-month 94 %;
12-month 83 %
NR
Hohla et al.13 6 2/6 (33) NR NR NR NR NR
Hosein et al.14 14 3/14 (21) 2/3 (67) NR NR NR –
Kraemer et al.15 7 1/7 (14) 0/1 (0) 0/1 (0) NR NR NR
Marthey et al.17 77 4/77 (5) – – – – 20/77 (26)
Sadot et al.21 101 15/101 (15) 11/14 (79)d 0/15 (0) 20/101 (20) – 14/101 (14)
Overall 292 29/242 (12) 14/20 (70) 0/18 (0) 39/173 (23) 34/178 (19)
Data are expressed as n (%) unless otherwise specified
OS overall survival, NR not reported, NA not applicable, NRE not reached, – indicates not reported separately for FOLFIRINOX, only combined
with radiotherapy (Table 2)
a Two patients died before the restaging scan
b Three patients refused treatment or were lost to follow-up
c One patient had a local recurrence
d One pathology report was pending
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Although no study directly compared outcomes after
FOLFIRINOX versus gemcitabine monotherapy in LAPC,
the results of FOLFIRINOX seem clearly superior to
gemcitabine, with reported response rates of 4.2–14.9 %
and a resection rate of only 7 %.29,30 Moreover, none of the
established therapies for LAPC have reported resection
rates similar to those of FOLFIRINOX reported in our
review.31
When addressing toxicity, our review shows remarkable
lower toxicity rates compared with the PRODIGE 4/
ACCORD 11 trial,3 which reported 46 % grade 3–4 neu-
tropenia compared with 19 % after FOLFIRINOX alone in
our review. In the PRODIGE/ACCORD trial, the median
number of treatment cycles administered was 10 and the
median relative dose intensities of fluorouracil, irinotecan,
and oxaliplatin were 82, 81 and 78 %, respectively. This
suggests that the reduced toxicity rate in our review is
probably explained by the administered modified regimens
by start and/or dose reductions during treatment, as
described in all included studies.
Our study has some limitations. First, the allocation of
FOLFIRINOX was often not based on predefined criteria
but at the discretion of the treating team. Therefore it is
inevitable that selection bias has occurred. No randomized
trials are performed and all studies reported only on patients
who actually received (or even completed) FOLFIRINOX
treatment. In other words, the percentage of patients with
LAPC not receiving FOLFIRINOX treatment and the sur-
vival in the entire cohort of LAPC were not reported.
Furthermore, only half of the studies reported the guidelines
used to establish resectability (Table 1). These guidelines
use various definitions.4,22 Moreover, studies reporting on
survival after resection with FOLFIRINOX in LAPC are
scarce and immature. Finally, the interventional treatment
was not standardized. Different dose reductions and modi-
fication schemes were applied and were not performed
according to a protocolled reduction schedule, but based on
the preference of the treating physician. In addition, the
radiotherapy regimens varied between the studies.
An important clinical question is how to decide which
patient may benefit from surgical exploration after FOL-
FIRINOX treatment. A recent study clearly demonstrated
that post-FOLFIRINOX CT-based treatment decision
making in pancreatic cancer is highly unreliable.24 In that
study, a senior pancreatic surgeon, blinded to FOLFIR-
INOX treatment, judged 19 of the 40 resected patients as
non-resectable based on post-FOLFIRINOX imaging;
however, all 40 patients underwent a resection, with a
remarkable 92 % R0 resection rate and a median overall
survival of 35 months for the entire group (19 LAPC and 9
borderline). Several other studies have also recommended
an exploratory laparotomy after induction therapy in the
absence of disease progression on subsequent imaging.32,33
These new insights on the low accuracy of CT imaging in
the assessment of resectability, and thus the recommen-
dation for surgical exploration after induction, suggest that
the resection rates demonstrated in these previously pub-
lished studies might currently be even higher in expert
centers. It is currently unclear whether a different approach
should be taken in patients with LAPC compared with
these series, which also included patients with borderline
resectable disease. Future studies should validate selection
criteria for surgical exploration. Improved imaging
modalities are urgently needed to improve the post-FOL-
FIRINOX decision-making process.
This review demonstrates the need for prospective
unselected studies with strict definitions, thus including
patients not receiving FOLFIRINOX. Such studies should
ideally report on consecutive patient (treatment) outcomes,
including quality of life, and on the overall survival of all
patients, especially those undergoing resection after FOL-
FIRINOX. Since a randomized controlled trial comparing
FOLFIRINOX with gemcitabine for LAPC seems unethi-
cal, future prospective unselected cohort studies are
recommended to investigate which patients might be eli-
gible for, and could benefit from, FOLFIRINOX and/or
multimodality treatments. Finally, studies should focus on
optimizing selection criteria for surgical exploration after
FOLFIRINOX in LAPC.24
CONCLUSIONS
Outcomes after FOLFIRINOX treatment in patients
with LAPC are promising, both for toxicity and (R0)
resection rates. Future unselected prospective cohort stud-
ies are needed to determine the exact role for
FOLFIRINOX in LAPC.
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